Afficher la notice abrégée

Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals

dc.rights.licenseopenen_US
hal.structure.identifierVirus et Immunité - Virus and immunity [CNRS-UMR3569]
dc.contributor.authorHUBERT, Mathieu
hal.structure.identifierVirus et Immunité - Virus and immunity [CNRS-UMR3569]
dc.contributor.authorGUIVEL-BENHASSINE, Florence
hal.structure.identifierVirus et Immunité - Virus and immunity [CNRS-UMR3569]
hal.structure.identifierVaccine Research Institute [Créteil, France] [VRI]
dc.contributor.authorBRUEL, Timothée
hal.structure.identifierVirus et Immunité - Virus and immunity [CNRS-UMR3569]
dc.contributor.authorPORROT, Françoise
hal.structure.identifierVirus et Immunité - Virus and immunity [CNRS-UMR3569]
hal.structure.identifierVaccine Research Institute [Créteil, France] [VRI]
dc.contributor.authorPLANAS, Delphine
hal.structure.identifierEnvironnement et Risques infectieux - Environment and Infectious Risks [ERI]
dc.contributor.authorVANHOMWEGEN, Jessica
hal.structure.identifierVaccine Research Institute [Créteil, France] [VRI]
hal.structure.identifierInstitut Mondor de Recherche Biomédicale [IMRB]
dc.contributor.authorWIEDEMANN, Aurélie
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorBURREL, Sonia
hal.structure.identifierInstitut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
hal.structure.identifierCHU Charles Foix [AP-HP]
dc.contributor.authorMAROT, Stéphane
hal.structure.identifierInstitut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
hal.structure.identifierCHU Charles Foix [AP-HP]
dc.contributor.authorPALICH, Romain
hal.structure.identifierInstitut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
hal.structure.identifierCHU Charles Foix [AP-HP]
dc.contributor.authorMONSEL, Gentiane
hal.structure.identifierVaccine Research Institute [Créteil, France] [VRI]
hal.structure.identifierInstitut Mondor de Recherche Biomédicale [IMRB]
dc.contributor.authorDIOMBERA, Harouna
hal.structure.identifierGroupe Henri Mondor-Albert Chenevier
dc.contributor.authorGALLIEN, Sébastien
hal.structure.identifierGroupe Henri Mondor-Albert Chenevier
dc.contributor.authorLOPEZ-ZARAGOZA, Jose Luis
hal.structure.identifierGroupe Henri Mondor-Albert Chenevier
dc.contributor.authorVINDRIOS, William
hal.structure.identifierCentre Médical de l'Institut Pasteur [CMIP]
dc.contributor.authorTAIEB, Fabien
hal.structure.identifierPlate-forme d’Investigation Clinique / Clinical Investigation Platform [ICAReB-Clin]
dc.contributor.authorFERNANDES-PELLERIN, Sandrine
hal.structure.identifierPlate-forme d’Investigation Clinique / Clinical Investigation Platform [ICAReB-Clin]
dc.contributor.authorDELHAYE, Maurine
hal.structure.identifierPlate-forme d’Investigation Clinique / Clinical Investigation Platform [ICAReB-Clin]
dc.contributor.authorLAUDE, Hélène
hal.structure.identifierPlate-forme d’Investigation Clinique / Clinical Investigation Platform [ICAReB-Clin]
dc.contributor.authorAROWAS, Laurence
hal.structure.identifierPlate-forme d’Investigation Clinique / Clinical Investigation Platform [ICAReB-Clin]
dc.contributor.authorUNGEHEUER, Marie-Noelle
hal.structure.identifierCentre Hospitalier Régional d'Orléans [CHRO]
dc.contributor.authorHOCQUELOUX, Laurent
hal.structure.identifierInstitut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
hal.structure.identifierCHU Charles Foix [AP-HP]
dc.contributor.authorPOURCHER, Valérie
hal.structure.identifierCentre Hospitalier Régional d'Orléans [CHRO]
dc.contributor.authorPRAZUCK, Thierry
hal.structure.identifierInstitut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
hal.structure.identifierCHU Charles Foix [AP-HP]
dc.contributor.authorMARCELIN, Anne-Geneviève
hal.structure.identifierVaccine Research Institute [Créteil, France] [VRI]
hal.structure.identifierInstitut Mondor de Recherche Biomédicale [IMRB]
hal.structure.identifierGroupe Henri Mondor-Albert Chenevier
dc.contributor.authorLELIÈVRE, Jean-Daniel
hal.structure.identifierEnvironnement et Risques infectieux - Environment and Infectious Risks [ERI]
dc.contributor.authorBATÉJAT, Christophe
hal.structure.identifierVaccine Research Institute [Créteil, France] [VRI]
hal.structure.identifierInstitut Mondor de Recherche Biomédicale [IMRB]
hal.structure.identifierGroupe Henri Mondor-Albert Chenevier
dc.contributor.authorLÉVY, Yves
hal.structure.identifierEnvironnement et Risques infectieux - Environment and Infectious Risks [ERI]
dc.contributor.authorMANUGUERRA, Jean-Claude
hal.structure.identifierVirus et Immunité - Virus and immunity [CNRS-UMR3569]
hal.structure.identifierVaccine Research Institute [Créteil, France] [VRI]
dc.contributor.authorSCHWARTZ, Olivier
dc.date.accessioned2024-04-24T10:42:49Z
dc.date.available2024-04-24T10:42:49Z
dc.date.issued2023-06-14
dc.identifier.issn1931-3128en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/199310
dc.description.abstractEnMpox virus (MPXV) caused a multi-country outbreak in non-endemic areas in 2022. Following historic success of smallpox vaccination with vaccinia virus (VACV)-based vaccines, the third generation modified vaccinia Ankara (MVA)-based vaccine was used as prophylaxis for MPXV, but its effectiveness remains poorly characterized. Here, we applied two assays to quantify neutralizing antibodies (NAbs) in sera from control, MPXV-infected, or MVA-vaccinated individuals. Various levels of MVA NAbs were detected after infection, historic smallpox, or recent MVA vaccination. MPXV was minimally sensitive to neutralization. However, addition of complement enhanced detection of responsive individuals and NAb levels. Anti-MVA and -MPXV NAbs were observed in 94% and 82% of infected individuals, respectively, and 92% and 56% of MVA vaccinees, respectively. NAb titers were higher in individuals born before 1980, highlighting the impact of historic smallpox vaccination on humoral immunity. Altogether, our results indicate that MPXV neutralization is complement dependent and uncover mechanisms underlying vaccine effectiveness.
dc.description.sponsorshipInitiative for the creation of a Vaccine Research Instituteen_US
dc.description.sponsorshipIntegrative Biology of Emerging Infectious Diseasesen_US
dc.description.sponsorshipProtéomique du SARS-CoV-2en_US
dc.description.sponsorshipConséquences de l'infection par le SRAS-CoV-2 sur la fonction mitochondriale - ANR-21-CO14-0007en_US
dc.language.isoENen_US
dc.subject.enmpox virus
dc.subject.enneutralizing antibodies
dc.subject.encomplement
dc.subject.ensmallpox vaccination
dc.subject.enhybrid immunity
dc.title.enComplement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.chom.2023.05.001en_US
dc.subject.halSciences du Vivant [q-bio]en_US
dc.identifier.pubmed37196656en_US
bordeaux.journalCell Host & Microbeen_US
bordeaux.page937-948.e4en_US
bordeaux.volume31en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.issue6en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhal-04309033
hal.version1
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cell%20Host%20&%20Microbe&rft.date=2023-06-14&rft.volume=31&rft.issue=6&rft.spage=937-948.e4&rft.epage=937-948.e4&rft.eissn=1931-3128&rft.issn=1931-3128&rft.au=HUBERT,%20Mathieu&GUIVEL-BENHASSINE,%20Florence&BRUEL,%20Timoth%C3%A9e&PORROT,%20Fran%C3%A7oise&PLANAS,%20Delphine&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée